Future Looks Bright For Ambitious Argenx

23 Aug 2018

Now that cash-rich Argenx has AbbVie fully onboard and a pipeline-in-a-product opportunity in efgartigimod moving smoothly through the clinic, the Belgian biotech is in for an interesting couple of years.

Bricklayer — AbbVie pact another brick in place for Argenx • Source: Shutterstock

With AbbVie Inc. licensing a preclinical immuno-oncology drug, and strong data backing its lead candidate efgartigimod, argenx SE of Belgium's antibody technology platform has been validated.

The AbbVie deal, announced Aug. 22, saw the US major has exercised an option it took out in April 2016...